News


All series


All News

A new retrospective analysis has suggested that the R-CHOP chemotherapy regimen of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone leads to superior outcomes compared to rituximab plus bendamustine in patients with grade 3A follicular lymphoma.

Lenvatinib in combination with everolimus improved progression-free survival in patients with advanced renal cell carcinoma compared with sunitinib, meeting the primary end point of the phase 3 KEYNOTE-581/CLEAR clinical trial. Pembrolizumab added to lenvatinib, another experimental arm of the trial, also achieved a satisfactory overall response rate, meeting a key secondary end point.

A broad range of patients with heavily pretreated relapsed/refractory lower-risk myelodysplastic syndrome who were ineligible for treatment with an erythropoiesis-stimulating agent achieved durable red blood cell transfusion independence following treatment with the imetelstat, according to results from the phase 2 IMerge trial.